Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC
Subcutaneous pembrolizumab is a viable treatment option for mNSCLC
Urine test could reduce post-op scans for kidney cancer by half
Micro-ultrasound is as effective as MRI in detecting prostate cancer
Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC
Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer
Adjuvant docetaxel shows no significant advantage compared to surveillance in high-risk prostate cancer after 10 years
TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy
EAU 2025: Updates in NMIBC
Enzalutamide with 5-ARI is safe for older patients with castration-sensitive systemic prostate cancer
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients